Investor Relations

Press Releases

June 12, 2026

Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes

Read the Press Release

June 10, 2026

Press Release: Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy

Read the Press Release

June 8, 2026

Press Release: Sanofi’s Sarclisa subcutaneous approved in the EU as the first anticancer treatment administered via an on-body injector

Read the Press Release

See more press releases

Upcoming Events

18Jun

2026

JPM European Healthcare Forum l London

Conferences

30Jul

2026

Second quarter 2026 results

Second quarter 2026 results will be reviewed by management during a live audio webcast with the financial community on July 30, 2026. The presentation will be followed by a Q&A session.

13:00 - 14:15 CET (7:00am - 8:15am EST)

Quarterly results

9Sep

2026

Kepler Cheuvreux Autumn Conference l Paris

Speaker : Thomas Grenier, Head of North America, Vaccines

Conferences

All our events

Female scientist in white lab coat and safety equipment working with a tablet at a laboratory workstation with protective hood

Shuang Yang, Scientist, China

2025 20-F

Presenting our 2025 FORM 20-F.

31st Consecutive Year of Dividend Increase

Learn more

Dr. Yohana Mokiwa has a serious expression, blue shirt and stethoscope, as he speaks with a patient in a pop up clinic

Dr. Yohana Mokiwa speaking with a patient in a pop-up clinic, Dar es Salaam, Tanzania

Environment, Social, Governance

As a global pharmaceutical company, we stretch everyday to deliver safe and sustainable innovation and play our part in addressing some of the world’s most pressing challenges.